Zandi is a qualified Accountant having achieved a B.Acc (cum laude), B.Acc (Hons)/CTA, CA(SA) as well as completing TOPP articles at Discovery Limited. She previously held the position of Head of Finance/CFO at a biotechnology start-up that was pioneering the first COVID-19 test kit in Africa. Prior to this she worked at a boutique advisory firm as their Corporate Finance Analyst. She is currently an Associate at Kleoss Capital.
Grant’s philosophy is to strive to leave a legacy of true value, providing healthcare access to previously disadvantaged people and better care for all. His passion and purpose within his career has led him to pursue lifelong education and become a keen researcher in every avenue that he pursues. His career spans from medical asset finance to the healthcare industry and managed care business. Before serving as CDE’s Board Member and current Chief Executive Offer to facilitate change management, he worked on a strategic turnaround that involved corporate restructuring activities and strategic consulting work for various companies and incorporated strategic re-positioning, product design and business process re-design. Over the years he has honed his skills in business rescue along with design, consulting, and oversight of disruptive business strategy.
Zain is a seasoned private equity professional with extensive experience across the entire private equity spectrum from fundraising to origination and exit including managing troubled assets. Zain also has successful turnaround experience across the African continent gained during his tenure at Emerging Capital Partners between 2006-2012. With seven funds and over $2.0 billion under management, ECP is a leading private equity manager focused exclusively on Africa.
Hale is the co-founder of Kleoss Capital and its Chief Executive Officer. He is responsible for overseeing the overall operations of Kleoss Capital and the Fund’s performance. This includes, inter alia, assisting the team with deal origination and execution, engagement with portfolio companies to drive the Fund’s value creation strategies and engagement with the Fund’s investors.